Loading...
Loading...
FENC| Name | Value |
|---|---|
| Revenues | 7,925.0K |
| Cost of Revenue | 669.0K |
| Gross Profit | 7,256.0K |
| Operating Expense | 8,190.0K |
| Operating I/L | -934.0K |
| Other Income/Expense | -686.0K |
| Interest Income | 374.0K |
| Pretax | -1,620.0K |
| Income Tax Expense | 365.0K |
| Net Income/Loss | -1,985.0K |
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company's primary source of revenue is expected to come from the commercialization of PEDMARK, once it receives regulatory approval. As a clinical-stage company, Fennec Pharmaceuticals Inc. is dedicated to advancing its product candidate through the development process to bring a potentially life-changing treatment to market.
